Xalud Therapeutics, Inc. Employee Directory
Biotechnology ResearchNew York, United States2-10 Employees
Xalud Therapeutics is a biotechnology company focused on non-viral gene therapies that aim to modulate the immune system to address pathologic inflammation. Its lead candidate, XT-150, is a locally injectable plasmid DNA therapy designed to produce interleukin-10, a cytokine that coordinates multiple inflammatory pathways. By targeting inflammatory drivers at their source, the approach seeks to reduce pain and help restore immune balance, with a focus on inflammatory conditions such as osteoarthritis-related pain. The company is based in New York, New York, and operates with a small team as a clinical-stage organization in the biotechnology research sector. It develops non-viral gene therapies to treat pathologic inflammation through immune modulation. In January 2024, reports noted a leadership change with the chief executive officer stepping down.